ALEC - Alector, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Alector, Inc.

131 Oyster Point Boulevard
Suite 600
South San Francisco, CA 94080
United States

Full Time Employees109

Key Executives

NameTitlePayExercisedYear Born
Dr. Tillman U. GerngrossCo-Founder & Chairman25kN/A1964
Dr. Arnon RosenthalCo-Founder, CEO & Director637.87kN/A1955
Dr. Robert Paul M.D., Ph.D.Chief Medical Officer508.28kN/A1968
Dr. Robert S. KingChief Devel. Officer502.42kN/A1963
Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A.Pres & COON/AN/A1971
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.

Corporate Governance

Alector, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.